CERTMEDIUM SIGNALFINANCIAL10-K

CERT substantially reduced net losses while expanding operations and strengthening cash generation capabilities.

The company's meaningful reduction in net losses combined with strong operating cash flow growth suggests improving operational efficiency and path toward profitability. However, rising interest expenses indicate increased debt burden that investors should monitor closely.

Comparing 2026-02-26 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

CERT demonstrated notable financial improvement with substantially reduced net losses and strong operating cash flow growth of nearly 20%. R&D investment increased modestly, reflecting continued innovation spending, while interest expenses rose meaningfully, suggesting higher debt levels. The overall picture signals improving operational performance and cash generation despite increased financing costs.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+86.8%
-$12.1M-$1.6M

Net income grew 86.8% — bottom-line growth signals improving overall business health.

Interest Expense
P&L
+28.9%
$17.8M$22.9M

Interest costs rose 28.9% — monitor debt levels and coverage ratio in rising rate environment.

Operating Cash Flow
Cash Flow
+19.7%
$80.5M$96.3M

Operating cash flow grew 19.7% — strong conversion of earnings to cash, healthy business fundamentals.

R&D Expense
P&L
+10.6%
$37.1M$41.0M

R&D investment increased 10.6% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-26
ADDED
As of February 17, 2026, the registrant had 159,139,562 shares of common stock, par value $0.01 per share, outstanding.
Our registered trademarks include Certara Phoenix, Simcyp, Pinnacle 21, CoAuthor, GlobalSubmit Certara D360, Chemaxon and Vyasa.
Operational disruptions, funding constraints and policy changes at the FDA and other government agencies could adversely affect regulatory activity and our business.
The loss of one or more of our major customers could materially and adversely affect our business, results of operations and/or financial condition.
Our Company We are a global leader in biosimulation science, technology, and consulting services for using Model-Informed Drug Development ( MIDD ) in the global biopharmaceutical and biotech industry.
+7 more — sign up free →
REMOVED
As of February 17, 2025, the registrant had 161,017,775 shares of common stock, par value $0.01 per share, outstanding.
Our registered trademarks include Certara , Phoenix , Simcyp , Pinnacle 21 , CoAuthor , GlobalSubmit , Certara D360 and Vyasa TM .
Our historic growth rates may not be sustainable or indicative of future growth.
We rely upon third-party providers of cloud-based infrastructure to host our software solutions.
Our Company We are a global leader in biosimulation technology and solutions for using Model-Informed Drug Development ( MIDD ) in the global biopharmaceutical industry.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →